These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 35917493

  • 1. SATB2 Expression in Human Tumors: A Tissue Microarray Study on More Than 15 000 Tumors.
    Dum D, Kromm D, Lennartz M, De Wispelaere N, Büscheck F, Luebke AM, Burandt E, Menz A, Kluth M, Hube-Magg C, Hinsch A, Höflmayer D, Weidemann S, Fraune C, Möller K, Lebok P, Sauter G, Simon R, Uhlig R, Wilczak W, Minner S, Krech R, Bernreuther C, Marx A, Steurer S, Jacobsen F, Clauditz T, Krech T.
    Arch Pathol Lab Med; 2023 Apr 01; 147(4):451-464. PubMed ID: 35917493
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer.
    Ma C, Olevian D, Miller C, Herbst C, Jayachandran P, Kozak MM, Chang DT, Pai RK.
    Mod Pathol; 2019 Jul 01; 32(8):1217-1231. PubMed ID: 30962505
    [Abstract] [Full Text] [Related]

  • 6. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
    Bellizzi AM.
    Histopathology; 2020 Jan 01; 76(2):251-264. PubMed ID: 31233624
    [Abstract] [Full Text] [Related]

  • 7. SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma: A Concise Review of Benefits and Pitfalls.
    Berg KB, Schaeffer DF.
    Arch Pathol Lab Med; 2017 Oct 01; 141(10):1428-1433. PubMed ID: 28968158
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin.
    Yang C, Sun L, Zhang L, Zhou L, Zhao M, Peng Y, Niu D, Li Z, Huang X, Kang Q, Jia L, Lai J, Cao D.
    Am J Surg Pathol; 2018 Feb 01; 42(2):160-171. PubMed ID: 28914716
    [Abstract] [Full Text] [Related]

  • 9. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
    Giannico GA, Gown AM, Epstein JI, Revetta F, Bishop JA.
    Hum Pathol; 2017 Sep 01; 67():152-159. PubMed ID: 28711650
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours.
    Hoskoppal D, Epstein JI, Gown AM, Arnold Egloff SA, Gordetsky JB, Shi CJ, Giannico GA.
    Histopathology; 2020 Mar 01; 76(4):550-559. PubMed ID: 31595536
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study.
    Mezheyeuski A, Ponten F, Edqvist PH, Sundström M, Thunberg U, Qvortrup C, Pfeiffer P, Sorbye H, Glimelius B, Dragomir A.
    Acta Oncol; 2020 Mar 01; 59(3):284-290. PubMed ID: 31769323
    [Abstract] [Full Text] [Related]

  • 14. Clinicopathological, immunohistochemical, and mutational analyses of pulmonary enteric adenocarcinoma: usefulness of SATB2 and β-catenin immunostaining for differentiation from metastatic colorectal carcinoma.
    Matsushima J, Yazawa T, Suzuki M, Takahashi Y, Ota S, Nakajima T, Yoshino I, Yokose T, Inoue T, Kawahara K, Nakatani Y.
    Hum Pathol; 2017 Jun 01; 64():179-185. PubMed ID: 28438615
    [Abstract] [Full Text] [Related]

  • 15. SATB2 is a novel marker of osteoblastic differentiation and colorectal adenocarcinoma.
    Ordóñez NG.
    Adv Anat Pathol; 2014 Jan 01; 21(1):63-7. PubMed ID: 24316906
    [Abstract] [Full Text] [Related]

  • 16. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
    Machado I, Navarro S, Picci P, Llombart-Bosch A.
    Pathol Res Pract; 2016 Sep 01; 212(9):811-6. PubMed ID: 27465835
    [Abstract] [Full Text] [Related]

  • 17. Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer.
    Nodin B, Johannesson H, Wangefjord S, O'Connor DP, Lindquist KE, Uhlén M, Jirström K, Eberhard J.
    Diagn Pathol; 2012 Aug 30; 7():115. PubMed ID: 22935204
    [Abstract] [Full Text] [Related]

  • 18. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.
    Sangoi AR, Kshirsagar M, Horvai AE, Roma AA.
    Int J Gynecol Pathol; 2017 Mar 30; 36(2):140-145. PubMed ID: 27294605
    [Abstract] [Full Text] [Related]

  • 19. Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer.
    Wang S, Zhou J, Wang XY, Hao JM, Chen JZ, Zhang XM, Jin H, Liu L, Zhang YF, Liu J, Ding YQ, Li JM.
    J Pathol; 2009 Sep 30; 219(1):114-22. PubMed ID: 19557828
    [Abstract] [Full Text] [Related]

  • 20. Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas.
    Davis JL, Horvai AE.
    Histopathology; 2016 Jul 30; 69(1):84-90. PubMed ID: 26644288
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.